Literature DB >> 26500065

A meta-analysis on selective versus comprehensive neck dissection in oral squamous cell carcinoma patients with clinically node-positive neck.

Lizhong Liang1, Tonghan Zhang2, Qianying Kong3, Jun Liang1, Guiqing Liao4.   

Abstract

OBJECTIVE: Properly management of cervical lymph node metastases is a critical treatment for patients with oral squamous cell carcinoma (OSCC). However there is no consensus on the optimal treatment for oral cancer patients with clinically node-positive (cN+) neck. This study aims to access the feasibility of selective neck dissection in oral cancer patients with cN+neck.
METHOD: We searched PubMed and EMBASE up to April 2015 to identify the studies which compared selective neck dissection (SND) with comprehensive neck dissection (CND) in OSCC patients with cN+neck. Data were extracted by two authors. The meta-analysis was conducted with regional recurrence and disease specific death as primary endpoints. RESULT: Five studies with a total of 443 patients met our inclusion criteria. No significant difference was found regarding regional recurrence, disease specific death or overall death between the SND and CND group.
CONCLUSION: These findings suggest that cN+OSCC patients treated with SND in conjunction with adjuvant therapy got comparable clinical outcome to CND.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinically node-positive neck; Meta-analysis; Oral squamous cell carcinoma; Selective neck dissection

Mesh:

Year:  2015        PMID: 26500065     DOI: 10.1016/j.oraloncology.2015.10.005

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  7 in total

1.  Is the prediction of one or two ipsilateral positive lymph nodes by computerized tomography and ultrasound reliable enough to restrict therapeutic neck dissection in oral squamous cell carcinoma (OSCC) patients?

Authors:  Karl Christoph Sproll; Sabina Leydag; Henrik Holtmann; Lara K Schorn; Joel Aissa; Patric Kröpil; Wolfgang Kaisers; Csaba Tóth; Jörg Handschel; Julian Lommen
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-01       Impact factor: 4.553

2.  Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.

Authors:  Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

3.  Loss of miR-16 contributes to tumor progression by activation of tousled-like kinase 1 in oral squamous cell carcinoma.

Authors:  Shousen Hu; Honghan Wang; Dan Yan; Wuhao Lu; Pei Gao; Weihua Lou; Xiangzhen Kong
Journal:  Cell Cycle       Date:  2018-10-09       Impact factor: 4.534

4.  How is neck dissection performed in Oral and Maxillofacial Surgery? Results of a representative nationwide survey among university and non-university hospitals in Germany.

Authors:  Andreas Pabst; Daniel G E Thiem; Elisabeth Goetze; Alexander K Bartella; Michael T Neuhaus; Jürgen Hoffmann; Alexander-N Zeller
Journal:  Clin Oral Investig       Date:  2021-03-29       Impact factor: 3.573

Review 5.  Prevalence of Metastasis and Involvement of Level IV and V in Oral Squamous Cell Carcinoma: A Systematic Review.

Authors:  Ahmad A Altuwaijri; Turki M Aldrees; Mohammed A Alessa
Journal:  Cureus       Date:  2021-12-07

6.  Analysis of the Role of Selective Neck Dissection in Clinically Node-Positive T3/T4 Oral Cancers.

Authors:  Dungala Dileep Maharaj; Rajkumar Kottayasamy Seenivasagam; Kinjal Shankar Majumdar; Abhinav Thaduri; Achyuth Panuganti; Pallvi Kaul; Jarang Rajesh Kumar; Nooruddin Mohammed
Journal:  Biomed Res Int       Date:  2022-02-10       Impact factor: 3.411

7.  Extent of neck dissection for patients with clinical N1 oral cancer.

Authors:  Yasumasa Kakei; Hirokazu Komatsu; Tsutomu Minamikawa; Takumi Hasegawa; Masanori Teshima; Hirotaka Shinomiya; Naoki Otsuki; Ken-Ichi Nibu; Masaya Akashi
Journal:  Int J Clin Oncol       Date:  2020-03-05       Impact factor: 3.402

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.